Key facts
- Aerwave Medical’s last known valuation is $14.0M (Feb 2021).
- It has raised $20.0M across 1 recorded rounds; the latest was Seed Round ($1.5M) in Jan 2021.
- Notable investors include Long Island High Technology Incubator, Lucius Partners.
- Aerwave Medical has filed 1 Form D with the SEC, most recently Jan 2021 ($1.5M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Aerwave Medical
Funding rounds
1 roundsAbout Aerwave Medical
Developer of interventional therapies intended to treat pulmonary diseases. The company offers alternative treatments to traditional medications for conditions such as asthma, COPD and other advanced lung diseases, enabling healthcare institutions to address a significant unmet medical need.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Website
- aerwavemed.com/
- Ownership
- Privately Held (backing)
Aerwave Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aerwave Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aerwave Medical in its N-PORT filings yet. We sweep new filings monthly.